Anna Fang
Founding Partner @ ZhenFund
Beijing, China
Anna Fang is a seed investor at ZhenFund in Beijing focused on Biotechnology and Medical. Anna Fang is based out of Beijing, Beijing and is the Founding Partner of ZhenFund. Anna previously worked at J.P. Morgan as a Investment Banking Analyst. Anna Fang attended the Stanford University and Columbia University.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Anna Fang invests in
Stages Anna Fang invests in
Countries Anna Fang invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Oncology 1 (25%)
- Consulting 1 (25%)
- Agriculture 1 (25%)
Country
- United States 2 (50%)
- China 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Meliora Therapeutics
|
Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications. | $11M / Seed / Sep 29, 2022 | |
|
Meliora Therapeutics
|
Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications. | $11M / Seed / Sep 29, 2022 | |
CellX
|
CellX is creating the world's first mushroom protein from morel mycelium fermentation. Our ingredient and product solutions can be applied to savory snacks, protein powders, and meat alternatives.We are also licensing existing IPs to help accelerate the commercialization of cultivated meat. Our technology offerings include suspension celllines and serum-free media that have achieved 30M/ml cell density and <$5/L media cost, tested at the 2,000L scale. | $4.3M / Seed / Mar 15, 2021 | |
Earli
|
Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous; and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers thatcancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics. | $19.5M / Seed / Sep 17, 2018 |
Co-Investors
About ZhenFund
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
ZhenFund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bob Xiaoping Xu
Founding Partner
|
|||
Emma Yin
Partner
|
|||
Lulu Sun
VP
|
|||
Tianyi Qin
Principal
|
|||
|
Anna Fang
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Anna Fang invest in?
Anna Fang invests primarily in Biotechnology, Medical and Oncology startups, most often at Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Anna Fang?
Public channels for Anna Fang include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Anna Fang last invest?
The most recent investment recorded for Anna Fang closed in Sep 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
